- Enzene inaugurated an 80,000-sq.-ft. biomanufacturing facility in Hopewell, New Jersey, marking its first major U.S. investment.
Enzene has inaugurated its first U.S. biomanufacturing facility in Hopewell, New Jersey. The 80,000-sq.-ft. site was officially opened by Governor Phil Murphy, who described the investment as a demonstration of the state’s role as a hub for global business and innovation.
The facility introduces Enzene’s EnzeneX™ 2.0 platform to the U.S. market. The technology, described as the world’s first fully connected continuous manufacturing system, is designed to be scalable and sustainable. According to the company, it can achieve up to ten times the yield of conventional biomanufacturing methods while lowering the cost of goods to $40 per gram.
The Hopewell site supports fed-batch drug substance manufacturing alongside continuous processes, with the aim of enhancing supply chain resilience across North America. Governor Murphy said the project would “ultimately create hundreds of jobs and generate $50 million in investment.”
Himanshu Gadgil, CEO of Enzene, said: “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”
The inauguration was attended by state and local officials, including the Mayor of Hopewell Township, Courtney Peters-Manning, and First Lady of New Jersey, Tammy Murphy, alongside representatives from federal offices.
